Travel grant 2019, Switzerland, Feb 5-7 2020

Important results from the project

** Denna text är maskinöversatt ** Sinfonia is a company that develops "precision therapies" for the treatment of genetically-driven and associated neurodegenerative diseases. Participating in forums, where investors and colleagues sharing the same objectives meet, is of the utmost importance to create financial and operational conditions to develop the company and its portfolio. The SwissBioNordic conference was a great example of this and I would like to thank all the organizers and participants for a very successful event! Johan Lundkvist, CEO Sinfonia Biotherapeutics

Expected long term effects

** Denna text är maskinöversatt ** -I gained a lot of new insights about entrepreneurship, which will help me in the continued work to develop Sinfonia in the future. - I created new contacts with different types of investors, which led to further discussions after the meeting. My hope is that these interactions will result in new investments in Sinfonia -Varumärket Sinfonia became more known, which is an important part of Sinfonia´s quest to become a leading player in the industry.

Approach and implementation

** Denna text är maskinöversatt ** The conference was well organized and created good opportunities for both pre-planned and spontaneous f2f meetings. The only improvement I can suggest is to split the company presentations into two sessions, with a huge coffee break / leg stretch in between. Now it was a single long session which made it difficult for the audience to manage to keep the energy and attention on top towards the end. It didn´t hit myself since I pitched Sinfonia as the second company in the morning.